Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jan 7, 2017 (10 years ago)

Montelukast sodium tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Discoloration: the firm received a complaint of a sealed bottle in which tablets inside had blue spots and a blue powder inside the bottle.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Montelukast sodium tablets, 10 mg, 30-count bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, By: HETERO Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India, NDC 31722-726-30

Affected NDC 31722-0726-30

Compare with the code on your package — it is the most precise check available.

Drug: Montelukast

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Montelukast Sodium
NDC 31722-0726
10 mg/1 Tablet, Film Coated
Oral
Camber Pharmaceuticals, Inc. Rx
Recalling firm
Hetero USA Inc
NDC code
31722-726-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0623-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Montelukast recalls

See all
Class II · Moderate risk

Montelukast Sodium Tablets

Presence of Foreign Tablet(s)/Capsule(s): A foreign tablet was found in a bottle of Montelukast Sodium Tablets, USP 10mg, identified as metoprolol 25 mg.

Terminated Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-725-10 D-0086-2024
Class II · Moderate risk

Montelukast Sodium Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-9438-3 D-0518-2023

Other recalls by Hetero USA Inc

All 2017 recalls
Class II · Moderate risk

Entecavir Tablets 0.5 mg

Failed Impurities/Degradation Specification: single unknown impurity OOS 0.33% (Limit:NMT 0.20%W/W) at the three month stability point.

Terminated Impurity / degradation Hetero USA Inc NDC 31722-833-30 D-1095-2017